Clopidogrel as a Perpetrator of Drug-Drug Interactions: A Challenge for Quantitative Predictions?

Clin Pharmacol Ther. 2019 Jun;105(6):1295-1299. doi: 10.1002/cpt.1398. Epub 2019 Mar 30.

Authors

Manthena V S Varma¹, Yi-An Bi¹, Sarah Lazzaro¹, Mark West¹

Affiliation

¹ Pharmacokinetics, Dynamics, and Metabolism, Medicine Design, Worldwide R&D, Pfizer, Inc., Groton, Connecticut, USA.

PMID: 30927478
DOI: 10.1002/cpt.1398

No abstract available

Publication types

Review

MeSH terms

Clopidogrel / adverse effects
Clopidogrel / metabolism*
Cytochrome P-450 CYP2C8 / metabolism
Drug Interactions / physiology*
Forecasting
Humans
Liver-Specific Organic Anion Transporter 1 / metabolism
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / metabolism*

Substances

Liver-Specific Organic Anion Transporter 1
Platelet Aggregation Inhibitors
SLCO1B1 protein, human
Clopidogrel
Cytochrome P-450 CYP2C8